Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Response to Letter to the Editor Regarding "Cligosiban for Premature Ejaculation: Success, Failure, or Insufficiently Tested?"

Althof SE, McMahon CG, Osterloh IH, Muirhead GJ.

J Sex Med. 2019 Nov;16(11):1864-1865. doi: 10.1016/j.jsxm.2019.08.023. No abstract available.

PMID:
31672288
2.

The Oxytocin Antagonist Cligosiban Fails to Prolong Intravaginal Ejaculatory Latency in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Phase IIb trial (PEDRIX).

Althof S, Osterloh IH, Muirhead GJ, George K, Girard N; PEDRIX Multi-Centre Study Group.

J Sex Med. 2019 Aug;16(8):1188-1198. doi: 10.1016/j.jsxm.2019.05.015.

PMID:
31351660
3.

The Oxytocin Antagonist Cligosiban Prolongs Intravaginal Ejaculatory Latency and Improves Patient-Reported Outcomes in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Trial (PEPIX).

McMahon C, Althof S, Rosen R, Giuliano F, Miner M, Osterloh IH, Muirhead GJ, Harty B; PEPIX Multi-Centre Study Group.

J Sex Med. 2019 Aug;16(8):1178-1187. doi: 10.1016/j.jsxm.2019.05.016.

PMID:
31351659
4.

Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects.

Muirhead GJ, Osterloh IH, Whaley S, van den Berg F.

J Sex Med. 2019 Feb;16(2):213-222. doi: 10.1016/j.jsxm.2018.11.012. Epub 2019 Jan 4.

PMID:
30612858
5.

Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.

Osterloh IH, Muirhead GJ, Sultana S, Whaley S, van den Berg F, Atiee G.

J Sex Med. 2018 Nov;15(11):1547-1557. doi: 10.1016/j.jsxm.2018.09.006. Epub 2018 Oct 16.

PMID:
30341006
6.

A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.

Pozniak AL, Boffito M, Russell D, Ridgway CE, Muirhead GJ.

Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:54-9. doi: 10.1111/j.1365-2125.2008.03136.x.

7.

The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.

Abel S, Russell D, Whitlock LA, Ridgway CE, Muirhead GJ.

Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:47-53. doi: 10.1111/j.1365-2125.2008.03135.x.

8.

Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.

Abel S, Jenkins TM, Whitlock LA, Ridgway CE, Muirhead GJ.

Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:38-46. doi: 10.1111/j.1365-2125.2008.03134.x.

9.

Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.

Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ.

Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:27-37. doi: 10.1111/j.1365-2125.2008.03133.x.

10.

Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.

Abel S, Russell D, Whitlock LA, Ridgway CE, Muirhead GJ.

Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:19-26. doi: 10.1111/j.1365-2125.2008.03132.x.

11.

Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers.

Abel S, van der Ryst E, Rosario MC, Ridgway CE, Medhurst CG, Taylor-Worth RJ, Muirhead GJ.

Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:5-18. doi: 10.1111/j.1365-2125.2008.03130.x.

12.

Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV.

Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman AN, Smith DA.

Drug Metab Dispos. 2005 Apr;33(4):587-95. Epub 2005 Jan 13.

PMID:
15650075
13.

The pharmacokinetics and hemodynamics of sildenafil citrate in male hemodialysis patients.

Grossman EB, Swan SK, Muirhead GJ, Gaffney M, Chung M, DeRiesthal H, Chow D, Raij L.

Kidney Int. 2004 Jul;66(1):367-74.

14.

The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes.

Christensen M, Andersson K, Dalén P, Mirghani RA, Muirhead GJ, Nordmark A, Tybring G, Wahlberg A, Yaşar U, Bertilsson L.

Clin Pharmacol Ther. 2003 Jun;73(6):517-28.

PMID:
12811361
15.

The effects of sildenafil on human sperm function in healthy volunteers.

Purvis K, Muirhead GJ, Harness JA.

Br J Clin Pharmacol. 2002;53 Suppl 1:53S-60S.

16.

The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers.

Muirhead GJ, Faulkner S, Harness JA, Taubel J.

Br J Clin Pharmacol. 2002;53 Suppl 1:37S-43S.

17.

The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.

Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B.

Br J Clin Pharmacol. 2002;53 Suppl 1:21S-30S.

18.

Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil.

Muirhead GJ, Rance DJ, Walker DK, Wastall P.

Br J Clin Pharmacol. 2002;53 Suppl 1:13S-20S.

19.
20.

Potential role for P-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man.

Abel S, Beaumont KC, Crespi CL, Eve MD, Fox L, Hyland R, Jones BC, Muirhead GJ, Smith DA, Venn RF, Walker DK.

Xenobiotica. 2001 Aug-Sep;31(8-9):665-76.

PMID:
11569532
21.

Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir.

Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N.

Br J Clin Pharmacol. 2000 Aug;50(2):99-107.

22.

Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina.

Webb DJ, Muirhead GJ, Wulff M, Sutton JA, Levi R, Dinsmore WW.

J Am Coll Cardiol. 2000 Jul;36(1):25-31.

23.

Ziprasidone and the pharmacokinetics of a combined oral contraceptive.

Muirhead GJ, Harness J, Holt PR, Oliver S, Anziano RJ.

Br J Clin Pharmacol. 2000;49 Suppl 1:49S-56S.

24.

Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man.

Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, Wright PA.

Xenobiotica. 1999 Mar;29(3):297-310.

PMID:
10219969
25.
26.

Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.

Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C.

Int J Impot Res. 1996 Jun;8(2):47-52.

PMID:
8858389
27.

Population pharmacodynamics of romazarit.

Holford NH, Williams PE, Muirhead GJ, Mitchell A, York A.

Br J Clin Pharmacol. 1995 Mar;39(3):313-20.

28.

Pharmacokinetics of 2-fluorodideoxycytidine (2FddC) in patients infected with human immunodeficiency virus.

Williams PE, Muirhead GJ, Sereni D, Rousseau FS, Edelman K, Hooker M.

Br J Clin Pharmacol. 1993 Mar;35(3):255-60.

29.

A pharmacokinetic and tolerance study of romazarit in patients with rheumatoid arthritis.

Williams PE, Bird HA, Minty S, Helliwell PS, Muirhead GJ, Bentley J, York A.

Biopharm Drug Dispos. 1992 Mar;13(2):119-29.

PMID:
1550907
30.

Pharmacokinetics and tolerance of romazarit after oral administration of ascending single doses to healthy human volunteers.

Williams PE, Muirhead GJ, Worth E, Zimmer R, Lücker P.

Eur J Drug Metab Pharmacokinet. 1990 Oct-Dec;15(4):317-22.

PMID:
2088768

Supplemental Content

Loading ...
Support Center